Envista Holdings Corporation
NVST
$27.64
-1.53%
Envista Holdings Corporation is a global dental products company that develops, manufactures, and markets a comprehensive portfolio of dental consumables, equipment, and services, operating through two primary segments: Specialty Products & Technologies and Equipment & Consumables. As a leading player in the dental industry, Envista is recognized for its innovative implant systems, orthodontic solutions, and digital dentistry technologies, serving dental professionals worldwide. The current investor narrative centers on the company's recovery and growth trajectory, driven by a 14.96% year-over-year revenue increase in Q4 2025, a return to profitability after a challenging 2024, and strategic focus on high-growth specialty products. Additionally, the stock has shown strong momentum, with a 34.82% gain over the past year, reflecting improving market sentiment and operational execution.…
NVST
Envista Holdings Corporation
$27.64
Investment Opinion: Should I buy NVST Today?
Rating: Buy. Envista is a compelling growth turnaround story with strong recent momentum. The consensus analyst rating is 'Buy' with an average target of $30.57, implying 8.9% upside. The thesis is supported by accelerating revenue growth (14.96% YoY in Q4), a return to profitability (net income of $32.9M), and expanding margins (operating margin up to 10.10%). The forward P/E of 16.90x is attractive relative to expected EPS growth to $1.97, and the P/S ratio of 1.34x is a discount to the industry average of 4.76x.
Sign up to view all
NVST 12-Month Price Forecast
The AI assessment is bullish on NVST, driven by strong operational momentum and a reasonable valuation. The company's revenue acceleration and margin expansion indicate a successful turnaround, and the forward P/E suggests the market is pricing in substantial earnings growth. However, the medium confidence reflects the risks of competitive pressures and macro volatility. If the company delivers on its EPS guidance and maintains growth, the stock could outperform. Key developments to watch include quarterly earnings, margin trends, and any changes in analyst sentiment. A downgrade to neutral would occur if revenue growth falls below 10% or if the stock trades above $31 without a corresponding increase in estimates.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Envista Holdings Corporation's 12-month outlook, with a consensus price target around $30.57 and implied upside of +10.6% versus the current price.
Average Target
$30.57
0 analysts
Implied Upside
+10.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$23 - $35
Analyst target range
Analyst coverage is robust with 14 analysts, and the consensus recommendation is 'Buy' with a mean rating of 2.19 (where 1 is Strong Buy and 5 is Sell). The average target price is $30.57, implying an upside of 8.9% from the current price of $28.07. The target range spans from $23.00 (low) to $35.00 (high), indicating a wide dispersion of expectations. The high target suggests potential for further upside if the company sustains its growth and margin expansion, while the low target reflects concerns about competitive pressures or execution risks. Recent ratings have been stable, with no major upgrades or downgrades, but the presence of multiple 'Neutral' ratings from firms like Mizuho and JP Morgan indicates a cautious optimism among some analysts.
Bulls vs Bears: NVST Investment Factors
Envista presents a compelling turnaround story with accelerating revenue growth, improving profitability, and expanding margins. The bull case is supported by strong Q4 2025 results, a return to positive earnings, and a reasonable forward valuation. However, the bear case highlights the high trailing P/E, revenue concentration, and recent price volatility. Currently, the bull case has stronger evidence, given the operational momentum and analyst optimism. The key tension is whether the company can sustain its growth and margin expansion to justify the forward earnings estimates, or if competitive pressures and macro headwinds will derail the recovery. If the company delivers on its EPS guidance of $1.97, the stock is undervalued; if not, it could face significant downside.
Bullish
- Strong Revenue Acceleration: Q4 2025 revenue grew 14.96% YoY to $750.6M, up from $652.9M in Q4 2024, and sequentially from $616.9M in Q1 2025. This marks a clear acceleration in top-line growth, driven by the Specialty Products & Technologies segment.
- Return to Profitability: Net income swung to $32.9M in Q4 2025 from a -$30.3M loss in Q3 2025, with EPS of $0.20. The company has now posted positive earnings in three of the last four quarters, indicating a sustainable turnaround.
- Expanding Margins: Gross margin improved to 55.04% in Q4 2025 from 54.47% in Q1 2025, while operating margin expanded to 10.10% from 6.32% over the same period. This demonstrates strong operational leverage and cost discipline.
- Attractive Forward Valuation: The forward P/E of 16.90x is reasonable for a company with expected EPS growth to $1.97, implying a PEG ratio of 0.86 (using forward growth). The P/S ratio of 1.34x is well below the industry average of 4.76x, suggesting undervaluation on sales.
Bearish
- High Trailing P/E: The trailing P/E of 77.54x is elevated, reflecting the low EPS of $0.36 over the past year. If earnings growth stalls, the stock could face multiple compression.
- Revenue Concentration Risk: The Specialty Products & Technologies segment generates $1.21B of the total revenue, making up a significant portion. Any disruption in this segment (e.g., competitive pressure in implants) could materially impact results.
- Negative PEG Ratio: The PEG ratio of -0.74 is negative due to recent losses, which complicates valuation analysis. This signals that the company is not yet consistently profitable, and the forward earnings estimates may be optimistic.
- Recent Price Volatility: The stock has seen a 6-month decline of -3.11% and a max drawdown of -25.97% over the past year. Despite the 1-year gain of +34.82%, the stock is prone to sharp pullbacks, as seen in the drop from $29.59 to $22.40 in early 2026.
NVST Technical Analysis
Envista's stock is in a clear uptrend, with a 1-year price change of +34.82%, significantly outperforming the S&P 500's +20.37% over the same period. The current price of $28.07 sits at 92.3% of its 52-week range (low $18.77, high $30.42), indicating the stock is trading near its highs, which suggests strong momentum but also potential overextension. The 6-month change of -3.11% shows a pullback from earlier peaks, yet the stock has recovered robustly, supported by a beta of 0.861, implying lower volatility than the market.
Beta
0.86
0.86x market volatility
Max Drawdown
-26.0%
Largest decline past year
52-Week Range
$19-$30
Price range past year
Annual Return
+33.9%
Cumulative gain past year
| Period | NVST Return | S&P 500 |
|---|---|---|
| 1m | +3.4% | +4.0% |
| 3m | +19.9% | +5.3% |
| 6m | -3.0% | +12.6% |
| 1y | +33.9% | +20.1% |
| ytd | +27.4% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NVST Fundamental Analysis
Envista's revenue trajectory is accelerating, with Q4 2025 revenue of $750.6 million, up 14.96% year-over-year, and sequential growth from $616.9 million in Q1 2025 to $669.9 million in Q3 2025. The Specialty Products & Technologies segment, generating $1.21 billion in revenue, is the primary growth driver, while Equipment & Consumables contributed $679.3 million. The company returned to profitability in Q4 2025 with net income of $32.9 million, a stark contrast to the Q3 2025 loss of -$30.3 million, and gross margin improved to 55.04% from 54.47% in Q1 2025. Operating margin expanded to 10.10% in Q4 2025 from 6.32% in Q1 2025, indicating strong operational leverage.
Quarterly Revenue
$750600000.0B
2025-12
Revenue YoY Growth
+15.0%
YoY Comparison
Gross Margin
55.0%
Latest Quarter
Free Cash Flow
$230400000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NVST Overvalued?
Given that Envista is profitable, the primary valuation metric is the P/E ratio. The trailing P/E stands at 77.54x, while the forward P/E is 16.90x, implying the market expects significant earnings growth. The gap between trailing and forward multiples suggests an anticipated EPS increase from $0.36 to $1.97, reflecting a turnaround narrative. The stock trades at a P/S ratio of 1.34x, below the industry average of 4.76x (based on historical data), indicating a discount on sales. However, the EV/EBITDA of 12.23x is moderate, and the PEG ratio is negative at -0.74, which is typical for a company with recent losses. The current P/B of 1.17x is near the lower end of its historical range (0.89x to 2.29x), suggesting the stock is not overvalued on a book basis.
PE
77.5x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 19x~55x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Envista's balance sheet shows a debt-to-equity ratio of 0.51, which is moderate but manageable. However, the company's net margin is thin at 1.73%, and it has a history of volatile earnings, including a -$1.15B net loss in Q2 2024 due to impairment charges. The company's cash flow generation is positive (FCF TTM of $230.4M), but the reliance on continued growth to justify the forward P/E of 16.9x is a risk. If revenue growth decelerates or margins compress, the stock could re-rate lower. Additionally, the company's revenue is concentrated in the Specialty Products segment, which could be vulnerable to shifts in dental spending.